Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,074 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.
Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P. Solares AM, et al. Among authors: diaz a. BMC Cancer. 2009 May 13;9:146. doi: 10.1186/1471-2407-9-146. BMC Cancer. 2009. PMID: 19439079 Free PMC article. Clinical Trial.
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Among authors: diaz a. Mol Cell Biochem. 2008 Sep;316(1-2):163-7. doi: 10.1007/s11010-008-9814-5. Epub 2008 Jun 25. Mol Cell Biochem. 2008. PMID: 18575815 Clinical Trial.
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Among authors: diaz a. Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7. Mol Cell Biochem. 2011. PMID: 21735096 Clinical Trial.
Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Pracoń R, Spertus JA, Broderick S, Bangalore S, Rockhold FW, Ruzyllo W, Demchenko E, Nageh T, Grossman GB, Mavromatis K, Manjunath CN, Smanio PEP, Stone GW, Mancini GBJ, Boden WE, Newman JD, Reynolds HR, Hochman JS, Maron DJ; ISCHEMIA Research Group. Pracoń R, et al. Circ Cardiovasc Interv. 2024 Apr 17:e013435. doi: 10.1161/CIRCINTERVENTIONS.123.013435. Online ahead of print. Circ Cardiovasc Interv. 2024. PMID: 38629312
Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study.
Golparian D, Cole MJ, Sánchez-Busó L, Day M, Jacobsson S, Uthayakumaran T, Abad R, Bercot B, Caugant DA, Heuer D, Jansen K, Pleininger S, Stefanelli P, Aanensen DM, Bluemel B, Unemo M; Euro-GASP study group. Golparian D, et al. Lancet Microbe. 2024 Apr 10:S2666-5247(23)00370-1. doi: 10.1016/S2666-5247(23)00370-1. Online ahead of print. Lancet Microbe. 2024. PMID: 38614111 Free article.
3,074 results